A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

NCT00861510 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, Mantle-cell
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Hairy Cell
Waldenstrom Macroglobulinemia
Multiple Myeloma

Interventions

DRUG: ON01910 Na

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)